Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Wednesday

Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) is set to announce its earnings results after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, topping the consensus estimate of $5.22 by $0.11. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business’s revenue was up 3043.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.39) EPS. On average, analysts expect Nektar Therapeutics to post $4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ NKTR traded up $1.72 during trading on Wednesday, hitting $39.23. 21,296 shares of the company were exchanged, compared to its average volume of 2,499,379. The firm has a market capitalization of $6.35 billion, a P/E ratio of -69.35 and a beta of 2.39. Nektar Therapeutics has a 1 year low of $22.92 and a 1 year high of $111.36. The company has a debt-to-equity ratio of 0.13, a quick ratio of 19.55 and a current ratio of 19.67.

Several equities research analysts have commented on NKTR shares. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research report on Monday, July 16th. Piper Jaffray Companies set a $125.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 25th. HC Wainwright restated a “hold” rating and set a $54.00 target price on shares of Nektar Therapeutics in a research report on Tuesday, July 31st. BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Mizuho restated a “buy” rating and set a $103.00 target price on shares of Nektar Therapeutics in a research report on Thursday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $82.91.

In other news, Director Jeffrey Robert Ajer sold 6,750 shares of Nektar Therapeutics stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $56.76, for a total transaction of $383,130.00. Following the completion of the transaction, the director now owns 15,750 shares of the company’s stock, valued at approximately $893,970. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis L. Winger sold 30,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $59.96, for a total value of $1,798,800.00. Following the transaction, the director now directly owns 57,750 shares of the company’s stock, valued at approximately $3,462,690. The disclosure for this sale can be found here. Insiders have sold a total of 96,000 shares of company stock valued at $5,825,680 in the last ninety days. Corporate insiders own 4.31% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Further Reading: What is intrinsic value?

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply